Gastrointestinal side effects, including constipation, nausea, and altered bowel habits, occur frequently with these medicines
This challenge is partly due to the increasing obesity prevalence and its impact on T2DM as well as T1DM pathophysiology and prognosis [15,16,17,18,19,20,21]
As of early 2026, California ended Medi-Cal coverage for GLP-1 medications prescribed solely for weight loss, citing unsustainable costs and long-term budget strain
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER The approval of a new higher dose will provide adult patients with an additional therapeutic option, offering the potential for greater weight loss, the agency stated
however, this approach is subject to much stricter criteria and may involve a long waiting list
Slow escalation significantly reduces early gastrointestinal symptoms and increases the likelihood of sustained therapy